Momenta Pharmaceuticals Inc. priced a common stock offering to raise about $225 million in gross proceeds.

The Cambridge, Mass.-based biotechnology company is selling 14,516,130 common shares at $15.50 apiece. Momenta has also granted underwriters a 30-day option to buy 2,177,419 additional shares for additional proceeds of about $33.7 million.

Goldman Sachs & Co. LLC and J.P. Morgan are joint lead book-running managers, while Stifel is a book-running manager for the offering.